WO2004024070A3 - Facteurs de liaison a des toxines bacteriennes - Google Patents

Facteurs de liaison a des toxines bacteriennes Download PDF

Info

Publication number
WO2004024070A3
WO2004024070A3 PCT/US2003/028282 US0328282W WO2004024070A3 WO 2004024070 A3 WO2004024070 A3 WO 2004024070A3 US 0328282 W US0328282 W US 0328282W WO 2004024070 A3 WO2004024070 A3 WO 2004024070A3
Authority
WO
WIPO (PCT)
Prior art keywords
stx
toxins
methods
subject
molecules
Prior art date
Application number
PCT/US2003/028282
Other languages
English (en)
Other versions
WO2004024070A2 (fr
Inventor
Joel Moss
Masatoshi Noda
Original Assignee
Us Gov Health & Human Serv
Univ Chiba
Joel Moss
Masatoshi Noda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Chiba, Joel Moss, Masatoshi Noda filed Critical Us Gov Health & Human Serv
Priority to AU2003267079A priority Critical patent/AU2003267079B2/en
Priority to CA002498225A priority patent/CA2498225A1/fr
Priority to JP2004536403A priority patent/JP2006508924A/ja
Priority to EP03749554A priority patent/EP1545209A4/fr
Publication of WO2004024070A2 publication Critical patent/WO2004024070A2/fr
Publication of WO2004024070A3 publication Critical patent/WO2004024070A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à des procédés de neutralisation de toxines bactériennes telles que des toxines Shiga et des toxines de choléra. Dans un mode de réalisation particulier, l'invention a trait à un procédé destiné au traitement d'un sujet souffrant d'une infection provoquée par un organisme de production de Stx par l'administration d'une quantité thérapeutiquement efficace d'un tannin de bractée de houblon dérivé de Humulus lupulus. L'invention a également trait à des composés permettant l'isolement de composés de liaison à des molécules Stx, et des procédés permettant la détection de la présence de molécules Stx dans un échantillon biologique. Dans un mode de réalisation de l'invention, un sujet infecté d'une souche E.coli de production de Stx est traité par l'administration entérique d'une fraction de poids moléculaire élevé d'un extrait de bractée de houblon au sujet.
PCT/US2003/028282 2002-09-10 2003-09-09 Facteurs de liaison a des toxines bacteriennes WO2004024070A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003267079A AU2003267079B2 (en) 2002-09-10 2003-09-09 Factors that bind intestinal toxins
CA002498225A CA2498225A1 (fr) 2002-09-10 2003-09-09 Facteurs de liaison a des toxines bacteriennes
JP2004536403A JP2006508924A (ja) 2002-09-10 2003-09-09 細菌毒素を結合する因子
EP03749554A EP1545209A4 (fr) 2002-09-10 2003-09-09 Facteurs de liaison a des toxines bacteriennes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40974202P 2002-09-10 2002-09-10
US60/409,742 2002-09-10

Publications (2)

Publication Number Publication Date
WO2004024070A2 WO2004024070A2 (fr) 2004-03-25
WO2004024070A3 true WO2004024070A3 (fr) 2004-08-05

Family

ID=31993998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028282 WO2004024070A2 (fr) 2002-09-10 2003-09-09 Facteurs de liaison a des toxines bacteriennes

Country Status (5)

Country Link
EP (1) EP1545209A4 (fr)
JP (1) JP2006508924A (fr)
AU (1) AU2003267079B2 (fr)
CA (1) CA2498225A1 (fr)
WO (1) WO2004024070A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237800A1 (en) 2002-04-05 2003-10-27 Government Of The United States, As Represented Bythe Secretary Of The Army Polymeric antioxidants
AU2005269754A1 (en) 2004-07-23 2006-02-09 Polnox Corporation Anti-oxidant macromonomers and polymers and methods of making and using the same
WO2006060801A2 (fr) 2004-12-03 2006-06-08 Polnox Corporation Processus pour la synthese d'antioxydants de polyalkylphenol
WO2006060800A1 (fr) 2004-12-03 2006-06-08 Polnox Corporation Synthese d'aniline, de macromonomeres antioxydants a base phenol et de polymeres correspondants
US7799948B2 (en) 2005-02-22 2010-09-21 Polnox Corporation Nitrogen and hindered phenol containing dual functional macromolecular antioxidants: synthesis, performances and applications
CA2606303A1 (fr) 2005-03-25 2006-10-05 Polnox Corporation Antioxydants macromoleculaires alkyles et polymeres et procedes pour les produire et les utiliser
WO2006116532A2 (fr) * 2005-04-28 2006-11-02 University Of Massachusetts Lowell Synthese d'oligo/poly(catechines) et methodes d'utilisation associees
EP1966293A1 (fr) 2005-10-27 2008-09-10 Polnox Corporation Compositions de polyolefines stabilisees
WO2007050985A2 (fr) 2005-10-27 2007-05-03 Polnox Corporation Antioxydants macromoleculaires a base de phenols et de phosphites a encombrement sterique
WO2007064843A1 (fr) 2005-12-02 2007-06-07 Polnox Corporation Compositions d’huile lubrifiante
WO2007102467A1 (fr) * 2006-03-07 2007-09-13 Keio University Solution aqueuse de conophylline et/ou de conophyllidine
WO2008005358A2 (fr) 2006-07-06 2008-01-10 Polnox Corporation Antioxydants macromoléculaires innovants comprenant des fragments antioxydants différents : structures, procédés de fabrication et d'utilisation
US7767853B2 (en) 2006-10-20 2010-08-03 Polnox Corporation Antioxidants and methods of making and using the same
JP2012153659A (ja) * 2011-01-27 2012-08-16 Akita Univ ホップ葉抽出物およびその製造方法
JP6232177B2 (ja) * 2011-11-28 2017-11-15 花王株式会社 ベロ毒素不活性化剤
EP3071544B1 (fr) 2013-11-22 2022-07-06 Polnox Corporation Antioxydants macromoléculaires basés sur deux types de fractions par molécule : structures, leurs procédés de fabrication et d'utilisation
WO2018160879A2 (fr) 2017-03-01 2018-09-07 Polnox Corporation Structures d'inhibiteurs de corrosion macromoléculaire (mcin), leurs procédés de fabrication et d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2986805B2 (ja) * 1989-05-19 1999-12-06 三井農林株式会社 細菌性外毒素に対する抗毒素剤
US6251461B1 (en) * 1997-10-10 2001-06-26 S. S. Steiner, Inc. Antimicrobial activity of hops extract against Clostridium botulinum, Clostridium difficile and Helicobacter pylori
CA2363454A1 (fr) * 1999-02-15 2000-08-17 The Nikka Whisky Distilling Co., Ltd. Utilisation de la proanthocyanidine
JP2000342192A (ja) * 1999-06-08 2000-12-12 Natl Fedelation Of Agricult Coop Assoc 浮腫病対策用飼料
JP2001249134A (ja) * 1999-12-28 2001-09-14 Matsushita Electric Ind Co Ltd タンパク質濃度計測用試薬、これを用いたタンパク質濃度計測方法および尿検査方法
JP4521703B2 (ja) * 2000-05-17 2010-08-11 アサヒビール株式会社 ホップより得られるリパーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAGASHIRA ET AL: "Inhibition by hop bract polyphenols of cellular adherence and water insoluble glucan synthesis of mutans streptococci", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 61, no. 2, 1997, pages 332 - 335, XP002978375 *

Also Published As

Publication number Publication date
CA2498225A1 (fr) 2004-03-25
JP2006508924A (ja) 2006-03-16
EP1545209A2 (fr) 2005-06-29
AU2003267079A1 (en) 2004-04-30
WO2004024070A2 (fr) 2004-03-25
AU2003267079B2 (en) 2008-08-14
EP1545209A4 (fr) 2009-07-29

Similar Documents

Publication Publication Date Title
WO2004024070A3 (fr) Facteurs de liaison a des toxines bacteriennes
Mbanga et al. Virulence gene profiles of avian pathogenic Escherichia coli isolated from chickens with colibacillosis in Bulawayo, Zimbabwe
WO2002058638A3 (fr) Medicaments a base de serpine pour le traitement de l'infection par vih et utilisation de ceux-ci
Almeida et al. Identification, isolation, and partial characterization of a novel Streptococcus uberis adhesion molecule (SUAM)
WO2008042481A3 (fr) Procédé permettant de détection et de neutraliser de bactéries
DK0759774T3 (da) Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
AU2016263700B2 (en) Staphylococcus lyase and use thereof
JP2006508924A5 (fr)
Thiyonila et al. Influence of tannase from Serratia marcescens strain IMBL5 on enhancing antioxidant properties of green tea
El Zawawy et al. Anti-proteolytic activity of Ganoderma lucidum methanol extract against Pseudomonas aeruginosa
Ahlawat et al. Proposed pathway of degradation of indigo carmine and its co-metabolism by white-rot fungus Cyathus bulleri
WO1998010076A3 (fr) Sequences d'adn et phospholipase d
WO2003087325A3 (fr) Methodes et compositions de prevention et de traitement d'infections microbiennes
Lievens et al. Dominant rhizosphere bacteria as a source for antifungal agents
Sabino et al. Exopolysaccharides produced by Bacillus spp. inhibit biofilm formation by Staphylococcus aureus strains associated with bovine mastitis
EP0835938A3 (fr) Topoisomérase I
CN113559259B (zh) 一种制备胡蜂毒素抗毒血清的方法
WO2003103699A8 (fr) Utilisation de ramoplanine pour traiter des troubles associes a la prise d'antibiotiques
Handayani et al. Staphylococcal Enterotoxin A Gene–Carrying Staphylococcus aureus Isolated from Foods and Its Control by Crude Alkaloid from Papaya Leaves
Ramachandran et al. Purification of azurin from Pseudomonas aeuroginosa
WO2004024099A3 (fr) Methodes et dispositifs de traitement d'infections bacteriennes peripheriques graves
Jura et al. Prevalence of selected immune evasion genes and clonal diversity in methicillin-susceptible Staphylococcus aureus isolated from nasal carriers and outpatients with cut wound infections
Tadepalli et al. Fusobacterium equinum possesses a leukotoxin gene and exhibits leukotoxin activity
Okochi et al. Target-selective photo-degradation of verotoxin-1 and reduction of its cytotoxicity to Vero cells using porphyrin–globotriose hybrids
ATE425986T1 (de) Antibakterielle behandlungsmethoden

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10526820

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2498225

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004536403

Country of ref document: JP

Ref document number: 2003267079

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003749554

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003749554

Country of ref document: EP